However, the treatment with IL-6 antagonistfailed in demonstrating a lower risk of VTE events in COVID-19 patients, but apotential confounding factor appears when administered simultaneously withstandard prophylactic anticoagulation [48]. Here, IL6 is linked to COVID-19.